What Are Imaging Biomarkers?

An imaging biomarker is a biological signature, which refers to a biomarker that can be detected in an image. With advances in computer technology, retinal imaging in ophthalmology has facilitated the discovery of potential imaging biomarkers in the eye. The potential advantages of imaging biomarkers are through the use of imaging equipment to objectively observe and measure characteristics. They include the potential to minimize subjective bias and inaccuracy due to inaccurate measurements, as well as the opportunity to blind images, standardize and centralize assessment. As of right now, qualitative and quantitative imaging biomarkers have provided significant context and predictive value for disease management in a wide range of retinal diseases.

Fig. 1. Schematic summarizing changes in various quantitative imaging biomarkers in (A) diabetic eye disease and (B) age-related macular degeneration. (Kalra G, et al., 2021)

Our Services

As a comprehensive ophthalmology preclinical CRO, Ace Therapeutics has successfully established an imaging core platform to support ophthalmology drug development. Our imaging core platform provides world class solutions in the development of ophthalmology imaging biomarkers.

With our imaging platform, we provide best-in-class end-to-end image management for ophthalmic research. In the preclinical arena, our optical imaging technology interrogates our customers' model systems in interesting ways. This allows realistic visualization of the pharmacodynamic effects of drugs and the response to therapy. In this way, drug development can be accelerated, time and cost reduced, and ultimately, revolutionized by the use of revolutionary AI insights to drive successful drug development.

General Strategies

For new potential imaging biomarkers, our scientists develop a complete analytical pipeline.

During the initial phase, including development, evaluation, and validation, the aim is to ensure that potential biomarkers are robust and fit for purpose. Technical validation includes assessment of single and multicenter accuracy, precision, repeatability, and reproducibility; biological and clinical validation ensures that biomarkers correlate with ophthalmic biology, outcome variables, and thus provide value to guide clinical decision-making.

What Can We Provide?

Our experienced scientists deliver results using leading-edge technology and advanced science. The process spans from image acquisition to precise and thorough analysis of data and provides you with:

• Discovery of structural biomarkers using optical coherence tomography, including layer-specific compartment assessment and interrogation of pathological features.
• Scan for vascular imaging biomarkers using ultra-widefield fluorescein angiography and OCT angiography, including quantitative leak signatures, ischemic burden, and vessel characteristics.
• Data processing and analysis of imaging biomarkers has become more precise using emerging technologies (including machine learning-based image evaluation systems).

Our Imaging Technology Platforms

• Computerized Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Single-photon Emission Computerized Tomography (SPECT)
• Optical Coherence Tomography (OCT)
• Ultrasoun
• X-Ray

Why Choose Us?

• Provide powerful detection methods and analysis methods that can be easily transferred across multiple platforms.
• Provide mechanism-of-action studies that can be linked to new therapeutic targets.
• Across multiple eye disease areas.

Ace Therapeutics offers comprehensive ocular imaging biomarkers services with its strong professional knowledge and technology platform. Our professional biomarker service team will determine the most suitable solution for your project based on your specific requirements. If you are interested in our services, please feel free to contact us.

Reference

1. Kalra G, Kar S S, Sevgi D D, et al. Quantitative Imaging Biomarkers in Age-Related Macular Degeneration and Diabetic Eye Disease: A Step Closer to Precision Medicine. J Pers Med. 2021;11(11):1161.

• Omics-Based Ocular Biomarker Discovery and Analysis Services
• Ocular Matrix Biomarker Discovery and Analysis Services
• Ocular Predictive Biomarker Identification Services
• Ocular Prognosis Biomarker Services
• Ocular Transformational Biomarker Services
• Ocular Pharmacodynamic Biomarker Services
• Custom Ocular Biomarker Development Services

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit